Your session is about to expire
← Back to Search
Antithrombotic Removal using DrugSorb-ATR system for Bleeding and Hemorrhage (STAR-T Trial)
STAR-T Trial Summary
This trial will test a new system for removing ticagrelor during surgery. The system will be compared to the standard method for removal, and the trial will measure safety and effectiveness.
- Postoperative Hemorrhage
- Hemorrhage
- Blood Loss
STAR-T Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSTAR-T Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.STAR-T Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Group 1: Control
- Group 2: DrugSorb-ATR Intervention
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many sites in North America are administering this research protocol?
"A total of 36 medical sites are offering this study, such as Lutheran Medical Group in Fort Wayne, Advent Health in Orlando, and University of Mississippi in Jackson."
How many participants are being recruited for this clinical trial?
"The clinical trial needs 120 compliant patients to be enrolled across multiple centres, including Lutheran Medical Group in Fort Wayne and Advent Health in Orlando. Those chosen must adhere to the inclusion criteria set forth by the study."
Are there any eligible participants for this research endeavor at present?
"Affirmative. The information found on clinicaltrials.gov verifies that this examination is presently enrolling patients, which was first made available to the public on August 31st 2021 and last modified on November 17th 2022. 120 individuals have to be recruited from 36 distinct locations for the trial to commence."
Share this study with friends
Copy Link
Messenger